Improving gene therapy and editing through advanced data analysis techniques.
Official title: Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences
Funded at Massmatrix, INC. · NIH-10881890 · Data updated 2026-11-12
This study is working on making new treatments for diseases by speeding up the process of reading DNA and RNA, so that patients can get these therapies faster and more effectively.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massmatrix, INC. NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 5, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $860,633 |
| NIH project number | 5R44GM152984-02 |
| Project ID | NIH-10881890 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with genetic disorders or diseases that could benefit from oligonucleotide-based therapies.
✕Less likely to help
Patients with conditions not related to genetic disorders or those who do not respond to oligonucleotide therapies may not benefit from this research.
What this research studies
This research focuses on enhancing the development of oligonucleotide-based therapies by utilizing advanced mass spectrometry data analysis. It aims to streamline the sequencing process of DNA and RNA, which is crucial for creating effective treatments. By implementing semi-automated sequencing on a high-throughput cloud platform, the project seeks to eliminate bottlenecks caused by manual data analysis, thereby accelerating the availability of these therapies to patients. The research also aims to improve the characterization of RNA modifications, which is essential for better biomarker identification.
Why it matters
Potential benefit: If successful, this research could lead to faster and more reliable gene therapies that improve patient outcomes.
How similar studies have gone: Previous research has shown promise in using advanced data analysis techniques to enhance gene therapy development, indicating a potential for success in this approach.
Where this research is happening
-
Massmatrix, INC.
Columbus, United States Active
Researchers
- Principal investigator: Johnson, George Hall — Massmatrix, INC.
- Study coordinator: Johnson, George Hall
Related research
Other NIH-funded projects on the same topics.
-
Improving mass spectrometry for better analysis of proteins and nucleic acids
This study is working on a new way to quickly and accurately measure the size of proteins and nucleic acids, which could help scientists better understand how these important molecules affect our health and diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.